Biotech company exclusively focused on enabling safer and more effective targeted cancer therapeutics - we love antibody-drug conjugates - connect to cure? SynAffix (spin-off of Radboud University in Nijmegen) is a protein engineering company focusing on technology development for next-generation site-specific antibody-drug conjugates (ADCs) for the treatment of cancer and other diseases.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/synaffix-bv” connections=”true” suffix=””]
SynAffix proprietary GlycoConnectTM technology, comprising precision modification of a mAbs native glycosylation site without requiring cell line engineering. SynAffix second ADC technology HydraSpaceTM further enables ADC therapeutics by increasing compatibility with highly hydrophobic payloads and allows two different drug mechanisms to be incorporated into a single ADC therapeutic (DAR2+2 _dual warheadÓ ADCs).
SynAffix is financially backed by Aravis, BioGeneration Ventures, BOM Capital and MS Ventures, the strategic corporate venture capital fund of Merck Serono.